Alnylam Pharmaceuticals Inc (ALNY)
Summary
Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns
I initiate coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, citing the recent pullback as an overreaction. AMVUTTRA now holds a near-term commercial monopoly in TTR silencing, with strong clinical data and $890 million in Q1 2026 revenue. ALNY's robust cash position ($3.0 billion) and GAAP profitability materially reduce investment risk and support pipeline development.
Jim Cramer Says Biotech is The Hottest Group in The Market Right Now
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.
Alnylam Pharmaceuticals Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 2,745 | $891,917.82 | $770,521.5 | -$121,396.32 | -13.61% |
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 132 | $31,596.16 | $37,052.4 | $5,456.24 | 17.27% |
| LC Lisa Candera CIGNA INVESTMENTS Inc. /NEW | 1,230 | $245,352.79 | $345,261 | $99,908.21 | 40.72% |
| CE Curtis Ellergodt Rothschild Investment LLC | 360 | $164,160 | $101,052 | -$63,108 | -38.44% |
 Dodge & Cox Dodge & Cox Funds | 3.35M | $331.31M | $940.84M | $609.53M | 183.98% |
Alnylam Pharmaceuticals Inc Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TA Tazeen Ahmad B of A Securities | 355.54 | $100,000 | $98,211.62 | -$1,788.38 | -1.79% |
Alnylam Pharmaceuticals Inc (ALNY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alnylam Pharmaceuticals Inc ever had a stock split?
Alnylam Pharmaceuticals Inc Profile
| Biotechnology Industry | Healthcare Sector | Dr. Yvonne L. Greenstreet M.B.A., M.D. CEO | NASDAQ (NGS) Exchange | 02043Q107 CUSIP |
| BR Country | 2,500 Employees | - Last Dividend | - Last Split | 28 May 2004 IPO Date |
Overview
Alnylam Pharmaceuticals, Inc. is a leading biopharmaceutical company that specializes in discovering, developing, and commercializing innovative therapeutics based on ribonucleic acid interference (RNAi). Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam is at the forefront of RNAi technology, employing this revolutionary science to tackle complex diseases at the genetic level. The company's commitment to innovation is underscored by its dynamic pipeline of products and its strategic collaborations with major players in the pharmaceutical industry, such as Regeneron Pharmaceuticals, Inc., Roche, Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. These partnerships aim to expand the potential of RNAi therapy across various diseases, including those affecting the eye, central nervous system (CNS), and more.
Products and Services
- ONPATTRO (patisiran)
Approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults, this product exemplifies Alnylam's commitment to addressing rare diseases with significant unmet needs.
- AMVUTTRA
Also targeting hATTR amyloidosis, AMVUTTRA is specifically approved for treating adults with polyneuropathy, showcasing the company's focused approach on this genetic disorder.
- GIVLAARI (givosiran)
For adults with acute hepatic porphyria (AHP), a rare metabolic disorder, GIVLAARI represents a significant advancement in treatment options, highlighting Alnylam's dedication to tackling challenging hepatic conditions.
- OXLUMO (lumasiran)
This product is designed for the treatment of primary hyperoxaluria type 1 (PH1), a rare genetic disorder, further demonstrating Alnylam's expertise in developing treatments for rare conditions.
- Development Pipeline
- Patisiran - in development for ATTR amyloidosis with cardiomyopathy.
- Cemdisiran - targeted to treat complement-mediated diseases.
- Belcesiran - for the treatment of alpha-1 liver disease.
- Elebsiran - aimed at chronic HBV infection treatment.
- Zilebesiran - under development to treat hypertension, in collaboration with Roche.
- ALN-APP - for Alzheimer's disease and cerebral amyloid angiopathy.
- ALN-HSD - targeted to treat NASH.
- Fitusiran - for the treatment of hemophilia, showcasing Alnylam's expansion into blood disorders.
- Inclisiran - aimed at treating hypercholesterolemia, highlighting Alnylam's foray into cardiovascular diseases.
- Vutrisiran - in phase 3 clinical trial for ATTR amyloidosis, underscoring ongoing commitment to this disease area.
